Dexamethasone beats placebo for cancer-related fatigue

Dexamethasone beats placebo for cancer-related fatigue
For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue, according to a study published online July 29 in the Journal of Clinical Oncology.

(HealthDay)—For patients with advanced cancer, dexamethasone is better than placebo for reducing cancer-related fatigue (CRF), according to a study published online July 29 in the Journal of Clinical Oncology.

Sriram Yennurajalingam, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues conducted a double-blind, placebo-controlled study to compare the effect of and placebo on CRF. Patients with three or more CRF symptoms of ?4 of 10 on the Edmonton Symptom Assessment Scale (ESAS) were randomized to receive dexamethasone (43 patients) or placebo (41 patients) orally twice per day for 14 days.

The researchers found that the mean improvement in the Functional Assessment of Chronic Illness-Fatigue (FACIT-F) subscale was significantly higher in the dexamethasone group than the at day 15. The dexamethasone group also experienced a significantly greater improvement in the FACIT-F total quality-of-life scores. At day 15, the mean differences in the ESAS score were significantly better for the dexamethasone group, but there was no difference in ESAS overall symptom distress or psychological distress score. Adverse event frequency did not differ significantly between the groups.

"In conclusion, we found dexamethasone to be more effective than placebo in reducing CRF in patients with advanced cancer," the authors write. "There was a significant improvement in quality of life, physical well-being, and physical distress. Larger long-term efficacy and safety studies are needed."

One author disclosed to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Prolonged dexamethasone cuts delayed nausea after chemo

Aug 22, 2012

(HealthDay) -- Adding dexamethasone to prochlorperazine on days two and three, following palonosetron and dexamethasone on day one, reduces delayed nausea (DN) in patients receiving chemotherapy containing ...

Treatment beneficial in smoldering multiple myeloma

Aug 01, 2013

(HealthDay)—For patients with smoldering multiple myeloma, treatment with lenalidomide plus dexamethasone correlates with delayed progression and improved survival, according to a study published in the ...

Recommended for you

Biomarker in aggressive breast cancer identified

8 hours ago

Two Northwestern University scientists have identified a biomarker strongly associated with basal-like breast cancer, a highly aggressive carcinoma that is resistant to many types of chemotherapy. The biomarker, ...

MRI better detects recurrent breast cancer

9 hours ago

(HealthDay)—Single-screening breast magnetic resonance imaging (MRI) detects 18.1 additional cancers after negative findings with mammography and ultrasonography (US) per 1,000 women with a history of breast ...

Natural (born) killer cells battle pediatric leukemia

21 hours ago

Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the lab, creating an army of natural killer cells that ...

User comments